Picard Medical, Inc. (PMI)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Picard Medical, Inc. (PMI) for alleged corporate wrongdoing. The firm is encouraging shareholders who purchased PMI securities before September 2, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.

Bragar Eagel & Squire, P.C., a shareholder rights law firm, has launched an investigation into Picard Medical, Inc. (NYSE:PMI) on behalf of long-term stockholders. This follows a class action complaint alleging a fraudulent stock promotion scheme involving social media misinformation and coordinated share dumping by insiders. The firm encourages investors who held Picard stock between September 2, 2025, and October 31, 2025, to contact them to discuss their legal options.

Picard Medical Inc. (NYSEAMERICAN: PMI) saw its shares jump by over 50% after reporting stronger-than-expected Q2 results, including a 39% revenue increase to US$2.95 million and a narrowed net loss. The company, through its SynCardia subsidiary, markets the only FDA and Health Canada approved total artificial heart, which serves as a temporary solution for transplant patients. Despite positive financial performance, the company faces persistent balance sheet concerns, but its long-term strategy focuses on developing the next-generation Emperor platform.

Shares of Picard Medical (NYSEAMERICAN:PMI) surged over 50% following a strong Q2 performance, driven by a 39% revenue increase and positive gross margins from its SynCardia artificial-heart division. Despite the significant stock rally and improved core business metrics, the company faces severe cash flow issues, holding only enough cash to cover 1.3 days of operating expenses as of June. The article highlights that while product sales improved and debt was reduced, the company's going concern status remains uncertain without securing new financing, especially given its high customer concentration and limited analyst coverage.

Picard Medical Inc. (PMI) stock has experienced a significant slide from the $5 area to around $3, driven by high volatility and a clear downtrend despite recent positive coverage. The company's financials show low revenue, steep net losses, and a tight balance sheet, making it a speculative small-cap with high dilution and financing risks. Short-term traders are focusing on the stock's chart-driven movements, recognizing its boom-and-fade structure and high intraday volatility for scalping and breakout opportunities.